Aileron Therapeutics, Inc. (ALRN) Stock

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. is a U.S.-based clinical-stage company specializing in chemoprotection oncology. Its primary therapeutic candidate, ALRN-6924, is currently being evaluated across multiple clinical trials for various cancer types. These include a Phase 1 trial for solid tumors and lymphoma, a Phase 2a clinical trial targeting peripheral T-cell lymphoma, and a Phase I trial for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Furthermore, ALRN-6924 is involved in combination studies: a Phase 1b trial testing its efficacy with cytarabine (Ara-C) in patients with MDS, and a Phase 2a combination trial with palbociclib for individuals with tumors exhibiting MDM2 amplifications co-amplifications, as well as for those with p53-mutated small cell lung cancer (the latter having already completed its Phase 1b clinical assessment). The company maintains license agreements with institutions such as the Dana-Farber Cancer Institute, Harvard College, and Umicore Precious Metals Chemistry USA, LLC. Established in 2001, the Boston, Massachusetts-headquartered firm was originally known as Renegade Therapeutics, Inc. before rebranding to Aileron Therapeutics, Inc. in February 2007.

Aileron Therapeutics, Inc. is headquartered in US.

Aileron Therapeutics, Inc. (ALRN) stock trades at $2.11 with a market capitalization of $45.72M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.11, reflecting a net loss over the last twelve months, price-to-book of 5.53, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.61 and $7.42, and currently trades 71.6% below its 52-week high.

On profitability, Aileron Therapeutics, Inc. generates a return on equity (ROE) of -163.66% (negative, reflecting a net loss), return on capital employed of -397.22%.

Official website: www.aileronrx.com